Allgenesis Biotherapeutics Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Taipei Taiwan (2014)

Organization Overview

First Clinical Trial
2018
NCT03533244
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Allgenesis Biotherapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

ag-73305 (1 trial)

ag-86893 (1 trial)

Drugs in Phase 1 Trials (1)

agn-232411 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pterygium (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3